Oura Faces Proposed Class Action Over Its 95% Sleep-Staging Accuracy Claim

Oura’s sleep-stage scores now face a legal challenge that reaches beyond one smart ring: a proposed class action alleges the company overstated what AI-generated sleep tracking can measure, despite marketing that cites 95% sleep-staging accuracy against a clinical sleep lab.

The suit, filed by Clarkson Law Firm in San Francisco, seeks class-action status and a jury trial over alleged false advertising. Its central accusation is not simply that a score can be imperfect. The complaint argues that Oura’s sensors and algorithms cannot detect the physiological signals needed to distinguish sleep stages accurately, so the company’s outputs are AI-generated estimates rather than the measurement its marketing implies.

The claim turns on what the ring can infer

Oura markets its wearables as tracking seven sleep elements, including REM and deep sleep, to generate a sleep score. The complaint specifically challenges the company’s comparison to a clinical sleep lab, arguing that laboratory sleep testing uses multiple electrodes to measure brain activity—equipment the plaintiffs say Oura’s products do not have.

• Oura’s marketing says its wearables track REM and deep sleep among seven sleep elements, and cites 95% sleep-staging accuracy compared with a clinical sleep lab.
• The complaint characterizes the resulting sleep-stage outputs as AI-generated guesses that are no better than a coin flip.

Useful estimates are not a diagnosis

The lawsuit arrives in a product category where the practical boundary is already contested. CNET senior editor Anna Gragert said trackers can flag potential symptoms that may prompt a conversation with a doctor, but they cannot diagnose and are not the same as medical equipment. For sleep scores and stages, she described the results as estimates and cautioned against overemphasizing one number.

That distinction gives the case its stakes. A company may present consumer sleep data as a helpful signal, while buyers may interpret a clinical comparison as evidence that the underlying stages have been measured with medical-level precision. The plaintiffs must still establish their allegations; the complaint has not resolved whether Oura’s advertised accuracy is misleading or whether its technology performs as claimed.

The case is only beginning

Oura disputes the allegations and says it intends to defend itself in court. It remains too early to know whether buyers will be able to join the proposed class or what compensation, if any, might result from a trial or settlement.

Oura also faces an ongoing class action alleging it collected sensitive personal information without customer consent for two years. That is a separate allegation, but together the cases put both the interpretation of health data and the handling of that data under legal scrutiny.